lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-11 and is reviewed periodically as new material appears.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
When the difference between successive pK values is about four or more, as in this example, each species may be considered as an acid in its own right; In fact salts of H2PO−4 may be crystallised from solution by adjustment of pH to about 5.5 and salts of HPO2−4 may be crystallised from solution by adjustment of pH to about 10. The species distribution diagram shows that the concentrations of the two ions are maximum at pH 5.5 and 10.
If it starts the mass killing of elements of the army, including officers who were not involved in the coup, this may trigger a "counter-coup" by soldiers who are afraid they will be next. To prevent such a desperate counter-coup that may be more successful than the initial attempt, governments usually resort to firing prominent officers and replacing them with loyalists instead. Notable counter-coups include the Ottoman countercoup of 1909, the 1960 Laotian counter-coup, the Indonesian mass killings of 1965–66, the 1966 Nigerian counter-coup, the 1967 Greek counter-coup, 1971 Sudanese counter-coup, and the coup d'état of December Twelfth in South Korea. A 2017 study finds that the use of state broadcasting by the putschist regime after Mali's 2012 coup did not elevate explicit approval for the regime.
Most navies prohibited women from serving on submarines, even after they had been permitted to serve on surface warships. The Royal Norwegian Navy became the first navy to allow women on its submarine crews in 1985. The Royal Danish Navy allowed female submariners in 1988. Others followed suit including the Swedish Navy (1989), the Royal Australian Navy (1998), the Spanish Navy (1999), the German Navy (2001) and the Canadian Navy (2002). In 1995, Solveig Krey of the Royal Norwegian Navy became the first female officer to assume command on a military submarine, HNoMS Kobben. On 8 December 2011, British Defence Secretary Philip Hammond announced that the UK's ban on women in submarines was to be lifted from 2013. Previously there were fears that women were more at risk from a build-up of carbon dioxide in the submarine. But a study showed no medical reason to exclude women, though pregnant women would still be excluded. Similar dangers to the pregnant woman and her fetus barred women from submarine service in Sweden in 1983, when all other positions were made available for them in the Swedish Navy. Today, pregnant women are still not allowed to serve on submarines in Sweden. However, the policymakers thought that it was discriminatory with a general ban and demanded that women should be tried on their individual merits and have their suitability evaluated and compared to other candidates. Further, they noted that a woman complying with such high demands is unlikely to become pregnant. In May 2014, three women became the RN's first female submariners.
Sources: en.wikipedia.org
Emma Barnett (born 5 February 1985); broadcaster and journalist for The Jewish Chronicle; main presenter of Woman's Hour on BBC Radio 4 since January 2021, and subsequently for the BBC Radio Four Today programme. Mir Basri, (Arabic: مير بصري; 1911-2006) was an Iraqi writer, economist, journalist, politician and poet. Among many public positions he held, Basri served as the head and central leader of Iraqi and Baghdad's Jewish community; joined the Iraqi Foreign Ministry, going on to hold a number of government positions including many relating to Iraq's Jewish community. He held many positions in Iraq, including: secretary of the advisory committee and supervisor of supply affairs, director general and secretary at the Iraqi Ministry of Foreign Affairs, undersecretary and director of protocol therein, and president of the Baghdad Chamber of Commerce. He also attended many international conferences representing Iraq. Basri also held the position of honorary president of the Jewish Community in Iraq during the late sixties and early seventies, and was economics columnist for the newspapers Al-Ikhwa Al-Watani, Al-Bilad, and Al-Shaab, and edited the weekly newspaper Al-Daleel. Rachel Beer, editor-in-chief of The Observer and The Sunday Times, born in Bombay to Sassoon David Sassoon, of the Iraqi Sassoon family. Rafael Behr (born June 1974), of South African Jewish ancestry; columnist at The Guardian, Financial Times; Jewish Chronicle; former political editor of the New Statesman.
Anti-parasitic: Calotropis extracts have been used in traditional medicine to treat parasitic infections. Some compounds in the plant have demonstrated activity against certain parasites. Calotropis contains toxic compounds, particularly in its latex and other plant parts. Using Calotropis for its potential medicinal properties, it's best to consult a qualified healthcare professional who can provide guidance based on your specific health needs and conditions.
Dehydrogenase and oxidase are easily distinguishable if one considers the electron acceptor. An oxidase will remove electrons from a substrate as well, but only uses oxygen as its electron acceptor. One such reaction is: AH2 + O2 ↔ A + H2O2. Sometimes an oxidase reaction will look like this: 4A + 4H+ + O2 ↔ 4A+ + 2H2O. In this case, the enzyme is taking electrons from the substrate, and using free protons to reduce the oxygen, leaving the substrate with a positive charge. The product is water, instead of hydrogen peroxide as seen above. An example of an oxidase that functions like this is complex IV in the Electron Transport Chain (ETC). Note that oxidases typically transfer the equivalent of dihydrogen (H2), and the acceptor is a dioxygen. Similarly, a peroxidase (another subclass of oxidoreductases) will use a peroxide (H2O2) as the electron acceptor, rather than an oxygen.
Can be used for purification on Protein-A Sepharose Designed Intrinsically Disordered tags containing disorder promoting amino acids (P,E,S,T,A,Q,G,..) Carbohydrate Recognition Domain or CRDSAT-tag, a protein which binds to lactose agarose or Sepharose
Sources: en.wikipedia.org
==== Class C sub-family ==== Class C enzymes are reported to play roles in biosynthesis of complex natural products and secondary metabolites. These enzymes methylate heteroaromatic substrates and are cobalamin-independent. These enzymes contain both the radical SAM motif and exhibit striking sequence similarity to coproporhyrinogen III oxidase (HemN), a radical SAM enzyme involved in heme biosynthesis Detailed mechanistic investigations on two class C radical SAM methylases have been reported: TbtI is involved in the biosynthesis of potent thiopeptide antibiotic thiomuracin. Jaw5 is suggested to be responsible for cyclopropane modifications.
a chiral stationary phase or a chiral additive in the mobile phase. The chiral stationary phase can be prepared by mixing chirally pure reagents such as L-amino acid, or brucine, or a chiral ligand exchange reagent with silica gel slurry, or by impregnation of the TLC plate in the solution of a chiral reagent. The principle can also be applied to chemically modify the stationary phase before making the plate via bonding of the chiral moieties of interest to the reactive groups of the layer material.
Paraquat, for instance, structurally resembles metabolized MPTP, which selectively kills dopaminergic neurons by inhibiting mitochondrial complex 1. It is widely used to model PD. A widely used herbicide, Paraquat has been epidemiologically linked to higher Parkinson's risk, and rodent studies show it causes mitochondrial dysfunction, oxidative stress, and dopaminergic neuron loss. Rotenone, a naturally derived insecticide, inhibits mitochondrial complex 1 and selectively damages dopaminergic neurons in the substantia nigra. Rodent studies show both temporary and chronic exposure can produce Parkinson-like pathology, including enteric nervous system changes. The dithiocarbamate fungicide Maneb, the second most commonly used pesticide in Brazil, interferes with mitochondrial respiration.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.